BYDUREON. IT IS HERE. AND SO FAR, SO GOOD

Persistance.  it has paid off for Amylin.  And so far, so good.

Late Friday, Amylin announced the approval of Bydureon. Although roughly a year late, it seems that the preparation time has paid off.

The market has reacted positively to the news and to the investor conference call late Friday.  this is in stark contrast to the original Byetta approval in 2005 when AMLN went down on approval.

We wish our friends at Amylin very well.  We are excited for you and the prospects of Bydureon.  It is a good drug, good data, and without the Lilly involvement, so far we have seen good execution.

 

Advertisements
Post a comment or leave a trackback: Trackback URL.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: